ALLMedicine™ Osteosarcoma Center
Research & Reviews 4,572 results
https://doi.org/10.1158/1078-0432.CCR-22-2912
Clinical Cancer Research : an Official Journal of the Ame... Udomruk S, Phanphaisarn A et. al.
Feb 4th, 2023 - Cell-free DNA analysis is a powerful tool for non-invasively predicting patient outcomes. We analyzed the size distribution of cfDNA and assessed its prognostic and diagnostic values in an osteosarcoma cohort. The fragment size distribution and le...
https://doi.org/10.1016/j.knee.2023.01.011
The Knee; Chen G, Li M et. al.
Feb 3rd, 2023 - Joint-preserving surgery is possible for patients with juxta-articular osteosarcoma of the knee, even when the tumor invades the epiphysis. Oncologic and functional outcomes may vary due to the extent of tumor invasion, the amount of epiphysis pre...
https://clinicaltrials.gov/ct2/show/NCT04974008
Feb 2nd, 2023 - This is a Phase 2, open-label, multicenter, single-arm study in patients (12-39 years) with a recent history of pulmonary recurrent osteosarcoma that has been completely resected. Planned enrollment is a maximum of 45 patients who will receive OST...
https://clinicaltrials.gov/ct2/show/NCT04833582
Feb 1st, 2023 - This is a phase 1/2 dose escalation and dose expansion study, evaluating the clinical activity and safety, pharmacodynamics, and pharmacokinetics of ZN-c3 in combination with gemcitabine in relapsed or refractory osteosarcoma.
https://clinicaltrials.gov/ct2/show/NCT04495790
Feb 1st, 2023 - It is estimated that between 50 and 80% of cancer patients in the United States (US) supplement their conventional medical treatment regimen with some form of complementary or alternative medicine (CAM) therapy or practice. A smaller percentage of...
Guidelines 4 results
https://doi.org/10.1016/j.otsr.2018.12.015
Orthopaedics & Traumatology, Surgery & Research : OTSR; Gomez-Brouchet A, Mascard E et. al.
Apr 10th, 2019 - Standardized reports are essential to meeting the bone sarcoma reference center certification requirements of the French National Cancer Institute (INCa). The usual classifications of the Musculoskeletal Tumor Society (MSTS), the American Joint Co...
https://doi.org/10.1093/annonc/mdu153
Annals of Oncology : Official Journal of the European Soc... Wilhelm M, Dirksen U et. al.
Jun 26th, 2014 - Teenagers and young adults (TYA) cancer contributes substantially to morbidity and mortality in a population with much to offer society. TYA place distinct challenges upon cancer care services, many reporting feeling marginalized and their needs n...
https://doi.org/10.1093/annonc/mdn102
Annals of Oncology : Official Journal of the European Soc... Bielack S, Carrle D et. al.
May 9th, 2008 - Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.|2008|Bielack S,Carrle D,Jost L, ,|diagnosis,epidemiology,pathology,therapy,therapy,diagnosis,epidemiology,pathology,therapy,
https://doi.org/10.1002/pbc.21596
Pediatric Blood & Cancer; Meyer JS, Nadel HR et. al.
May 6th, 2008 - The Children's Oncology Group (COG) is a multi-institutional cooperative group dedicated to childhood cancer research that has helped to increase the survival of children with cancer through clinical trials. These clinical trials include a standar...
Drugs 42 results see all →
Clinicaltrials.gov 258 results
https://clinicaltrials.gov/ct2/show/NCT04974008
Feb 2nd, 2023 - This is a Phase 2, open-label, multicenter, single-arm study in patients (12-39 years) with a recent history of pulmonary recurrent osteosarcoma that has been completely resected. Planned enrollment is a maximum of 45 patients who will receive OST...
https://clinicaltrials.gov/ct2/show/NCT04495790
Feb 1st, 2023 - It is estimated that between 50 and 80% of cancer patients in the United States (US) supplement their conventional medical treatment regimen with some form of complementary or alternative medicine (CAM) therapy or practice. A smaller percentage of...
https://clinicaltrials.gov/ct2/show/NCT04833582
Feb 1st, 2023 - This is a phase 1/2 dose escalation and dose expansion study, evaluating the clinical activity and safety, pharmacodynamics, and pharmacokinetics of ZN-c3 in combination with gemcitabine in relapsed or refractory osteosarcoma.
https://clinicaltrials.gov/ct2/show/NCT02107963
Feb 1st, 2023 - Background GD2 is a well-characterized tumor antigen in neuroblastoma, which is also expressed on osteosarcomas and some other sarcomas. T cells expressing 1st generation anti-GD2 chimeric antigen receptors (CARs) were safe and mediated modest ant...
https://clinicaltrials.gov/ct2/show/NCT04851119
Jan 31st, 2023 - PRIMARY OBJECTIVES: I. To estimate the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of tegavivint administered as an intravenous (IV) infusion over 4 hours, once weekly for 3 weeks, followed by a 1 week rest, in a 28-day cyc...
News 214 results
https://www.medpagetoday.com/hematologyoncology/othercancers/102805
Jan 26th, 2023 - Almost half of patients with advanced solid tumors or lymphomas experienced disease control with a drug that reactivates the TP53 tumor suppressor, a first-in-human study showed. Overall, the oral murine double minute-2 (MDM2) inhibitor milademeta...
https://www.onclive.com/view/fda-approval-insights-sodium-thiosulfate-in-cisplatin-treated-pediatric-solid-tumors
Oct 24th, 2022 - Welcome to OncLive On Air®! I’m your host today, Ashling Wahner. OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and ...
https://www.onclive.com/view/pedmark-reduces-ototoxicity-risk-in-cisplatin-treated-pediatric-solid-tumors
Oct 19th, 2022 - Sodium thiosulfate (Pedmark) has shown promise as an ototoxicity-mediating agent in pediatric patients with solid tumors treated with cisplatin, according to Nilay Shah, MD. He noted that additional research is needed to determine the long-term ef...
https://www.onclive.com/view/dinutuximab-plus-gm-csf-does-not-improve-dcr-in-recurrent-osteosarcoma
Oct 14th, 2022 - The combination of dinutuximab (Unituxin) plus granulocyte-macrophage colony-stimulating factor (GM-CSF) did not improve disease control rate (DCR) vs historical standards in patients with recurrent pulmonary osteosarcoma in complete surgical remi...
https://www.onclive.com/view/fda-approves-pedmark-for-prevention-of-platinum-induced-ototoxicity-in-pediatric-solid-tumors
Sep 20th, 2022 - The FDA has approved sodium thiosulfate (Pedmark) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients aged 1 month and older with localized, nonmetastatic solid tumors.1 The efficacy of the product was examined in pe...